AndhraNews.net
Home » Features » Companies » ThromboGenics

ThromboGenics


About ThromboGenics

ThromboGenics is a biotechnology company focused on the discovery and development of biopharmaceuticals for the treatment of eye disease, vascular disease and cancer. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent in stroke. ThromboGenics is also developing novel antibody therapeutics in collaborationwith BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR.

In November 2008, the company announced promising six month follow-up results from its phase IIb trial of Microplasmin (MIVI III) for treatment of visual disorders.

ThromboGenics in News

Diabetic Retinopathy Market to Reach $10.11 Billion by 2022: Grand View Research, Inc.
Global Diabetic Retinopathy Market is expected to reach USD 10.11 billion by 2022, according to a new study by Grand View Research Inc. Diabetic retinopathy is considered as a serious sight threatening complication that results due to long term diabetes

Investment Fund Manager, Chris Buyse, Appointed to Orgenesis Board
Orgenesis Inc. (OTCQB: ORGS), a cell therapy and regenerative medicine company with a novel therapeutic technology dedicated to converting a patient's own cells into functioning insulin-producing cells as a treatment for diabetes, today announced that Chris Buyse has been appointed to the Orgenesis board of directors.

Novartis demonstrates leadership in ophthalmology with new products and over 40 abstracts at EURETINA
Novartis International AG /Novartis demonstrates leadership in ophthalmology with new products and over 40 abstracts at EURETINA . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Alcon receives positive NICE recommendation for Jetrea® to treat eligible patients with vitreomacular traction, including macular hole
Novartis International AG /Alcon receives positive NICE recommendation for Jetrea® to treat eligible patients with vitreomacular traction, including macular hole . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Alcon announces EU approval of Jetrea®, first and only eye drug to treat sight-threatening vitreomacular traction and macular hole
Novartis International AG /Alcon announces EU approval of Jetrea®, first and only eye drug to treat sight-threatening vitreomacular traction and macular hole . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Novartis delivers strong innovation in 2012, offsetting patent expirations; next growth phase expected to begin in 2013
Novartis International AG /Novartis delivers strong innovation in 2012, offsetting patent expirations; next growth phase expected to begin in 2013 . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Jetrea(TM) receives positive CHMP opinion, would become the first drug to treat sight-threatening vitreomacular traction and macular hole
Novartis International AG /Jetrea(TM) receives positive CHMP opinion, would become the first drug to treat sight-threatening vitreomacular traction and macular hole . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Thrombogenics CEO Discusses Product Pipeline Ahead of Catalyts, FDA Review
In an exclusive interview with PropThink.com, Thrombogenics (EBR:THR)(OTC:TBGNF) CEO Patrik De Haes discusses the company's pending FDA and EMA approvals of ocriplasmin, a treatment for symptomatic vitreomacular adhesion. Current procedures in the 500,000 patient market require a week-long recovery period in which the patient remains immobilized face-down

Alcon gains exclusive ex-US rights for ocriplasmin, potential first pharmacological treatment for symptomatic vitreomacular adhesion
Novartis International AG /Alcon gains exclusive ex-US rights for ocriplasmin, potential first pharmacological treatment for symptomatic vitreomacular adhesion . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

OctoPlus announces the proposal to appoint Staf Van Reet to the Supervisory Board
OctoPlus N.V. ("OctoPlus" or the"Company") (Euronext: OCTO) announces today that the Supervisory Board oftheCompany plans to propose Dr. Staf Van Reet as chairman of the SupervisoryBoardat the next General Meeting of Shareholders in May. This appointment willbe fora period of four years. Dr. Van Reet has a long track record of successes in the pharma andbiotechindustry

Carling Communications, Inc. Hired as Agency of Record by ThromboGenics, Inc.
San Diego based healthcare communications agency, Carling Communications, Inc. has been chosen by ThromboGenics, Inc. as its agency of record for its brand development, promotional planning, and medical education efforts

Comment on this story

Share